Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials
- PMID: 26670422
- DOI: 10.1111/jth.13230
Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials
Abstract
ESSENTIALS: Most anticoagulant therapy has failed to demonstrate a survival benefit in the overall sepsis population. We conducted separate meta-analyses of anticoagulant therapy in three different populations. Survival benefit was observed only in the septic disseminated intravascular coagulation (DIC) population. Further randomized controlled trials should focus on specific populations with septic DIC.
Background: Although many preclinical trials have indicated the effectiveness and safety of anticoagulant therapy as an adjuvant therapy against sepsis, there is little evidence to support its effectiveness to reduce mortality in the overall population with sepsis in clinical situations. However, several studies suggested that specific anticoagulant therapy may potentially reduce mortality in patients with sepsis-induced disseminated intravascular coagulation (DIC).
Objective: We investigated whether the survival benefit of anticoagulant therapy might pertain to the coagulopathic population with sepsis.
Methods: We conducted separate meta-analyses of randomized controlled trials for anticoagulant therapy in three different populations: (i) overall population with sepsis, (ii) population with sepsis-induced coagulopathy, and (iii) population with sepsis-induced DIC. We searched MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials comparing anticoagulant therapy with placebo or no intervention in sepsis patients. We measured all-cause mortality as the primary outcome and bleeding complications as the secondary outcome.
Results: We analyzed 24 trials enrolling 14 767 patients. There were no significant reductions in mortality in the overall sepsis population and the population with sepsis-induced coagulopathy. Otherwise, we observed significant reductions in mortality (risk ratio 0.72, 95% confidence interval 0.62-0.85) in the population with sepsis-induced DIC. As adverse events, bleeding complications tended to increase similarly with anticoagulant therapy in all three populations.
Conclusion: Although associated with an increased risk of bleeding, anticoagulant therapy resulted in no survival benefits in the overall sepsis population and even the population with sepsis-induced coagulopathy; beneficial effects on mortality were observed only in the population with sepsis-induced DIC.
Keywords: anticoagulants; blood coagulation disorders; disseminated intravascular coagulation; meta-analysis; sepsis.
© 2015 International Society on Thrombosis and Haemostasis.
Comment in
-
Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials: comment.J Thromb Haemost. 2016 Nov;14(11):2308-2309. doi: 10.1111/jth.13394. Epub 2016 Sep 17. J Thromb Haemost. 2016. PMID: 27331770 No abstract available.
-
Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials: reply.J Thromb Haemost. 2016 Nov;14(11):2310-2311. doi: 10.1111/jth.13473. Epub 2016 Sep 30. J Thromb Haemost. 2016. PMID: 27537607 No abstract available.
Similar articles
-
Identifying Sepsis Populations Benefitting from Anticoagulant Therapy: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model.Thromb Haemost. 2019 Nov;119(11):1740-1751. doi: 10.1055/s-0039-1693740. Epub 2019 Aug 13. Thromb Haemost. 2019. PMID: 31408900
-
Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan.Crit Care. 2016 Jul 29;20(1):229. doi: 10.1186/s13054-016-1415-1. Crit Care. 2016. PMID: 27472991 Free PMC article. Clinical Trial.
-
Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):8S-28S. doi: 10.1177/1076029618806424. Epub 2018 Oct 8. Clin Appl Thromb Hemost. 2018. PMID: 30296833 Free PMC article.
-
The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation.Thromb Res. 2013 May;131(5):383-9. doi: 10.1016/j.thromres.2013.03.012. Epub 2013 Apr 6. Thromb Res. 2013. PMID: 23566533 Review.
-
Optimal patient selection for anticoagulant therapy in sepsis: an evidence-based proposal from Japan.J Thromb Haemost. 2018 Mar;16(3):462-464. doi: 10.1111/jth.13946. Epub 2018 Jan 29. J Thromb Haemost. 2018. PMID: 29316171 Review.
Cited by
-
Practical approach to thrombocytopenia in patients with sepsis: a narrative review.Thromb J. 2024 Jul 22;22(1):67. doi: 10.1186/s12959-024-00637-0. Thromb J. 2024. PMID: 39039520 Free PMC article. Review.
-
Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis.Sci Rep. 2022 Jun 3;12(1):9304. doi: 10.1038/s41598-022-13346-3. Sci Rep. 2022. PMID: 35660774 Free PMC article.
-
Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments.Open Access Emerg Med. 2017 Dec 28;10:25-29. doi: 10.2147/OAEM.S135909. eCollection 2018. Open Access Emerg Med. 2017. PMID: 29343993 Free PMC article. Review.
-
Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.Mol Pharmacol. 2020 Nov;98(5):612-619. doi: 10.1124/molpharm.120.000098. Epub 2020 Sep 10. Mol Pharmacol. 2020. PMID: 32913137 Free PMC article. Review.
-
Outcomes of continuous kidney replacement therapy in pediatric patients: the impact of timing and predictors of mortality.Pediatr Nephrol. 2025 Sep;40(9):2973-2980. doi: 10.1007/s00467-025-06794-2. Epub 2025 May 14. Pediatr Nephrol. 2025. PMID: 40366406
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials